Millipore Sigma Vibrant Logo
Atención: Nos hemos mudado. Los productos Merck Millipore ya no pueden adquirirse en MerckMillipore.comMás información

07-1533 Anti-JMJD3 (NT) Antibody

07-1533
400 µL  
Purchase on Sigma-Aldrich

Ofertas especiales

Descripción

Replacement Information

Ofertas especiales

Tabla espec. clave

Species ReactivityKey ApplicationsHostFormatAntibody Type
H, MIHC, ICC, ELISA, WBRbPurifiedPolyclonal Antibody
Description
Catalogue Number07-1533
DescriptionAnti-JMJD3 (NT) Antibody
Alternate Names
  • JMJD
  • JmjC domain-containing protein 3
  • Jumonji domain-containing protein 3
  • Lysine demethylase 6B
  • jumonji domain containing 3
  • jumonji domain containing 3
  • histone lysine demethylase
Background InformationJMJD3 (Jumonji domain-containing protein 3) is part of the family of novel JmjC domain-containing histone demethylation (JHDM) enzymes. Histone demethylation by JHDM proteins requires cofactors Fe(II) and alpha-ketoglutarate. JMJD3 specifically demethylates Lys27 on histone H3, demethylating both the trimethylated and dimethylated form. JMJD3 plays a role in the regulation of posterior development by regulating HOX gene expression. It is also involved in the inflammatory response by regulating gene expression and macrophage differentiation
References
Product Information
FormatPurified
Control
  • HeLa cells
PresentationPurified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide.
Quality LevelMQ100
Applications
ApplicationUse Anti-JMJD3 (N-terminus) Antibody (Rabbit Polyclonal Antibody) validated in IHC, ICC, ELISA, WB to detect JMJD3 (N-terminus) also known as JmjC domain-containing protein 3.
Key Applications
  • Immunohistochemistry
  • Immunocytochemistry
  • ELISA
  • Western Blotting
Application NotesELISA:
This antibody is reported by an
outside laboratory to be suitable for ELISA.

Immunohistochemistry:
This antibody is reported by an outside laboratory to be suitable for immuno-histochemistry.

Immunocytochemistry Analysis:
Confocal immunofluorescence analysis of HeLa and NIH/3T3 using 1:100 dilution of anti-JMJD3 (N-Terminus) (Red). Actin filaments have been labeled with Alexa Fluor 488 -Phalloidin (Green).

Western Blot Analysis:
The antibody recognizes JMJD3 in HeLa cell lysates.
Biological Information
ImmunogenThis antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human JMJD3.
EpitopeN-terminus
ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
HostRabbit
SpecificityRecognizes the N-terminal region of human JMJD3. Additional lower MW bands are detected in some lysates that may be degradation products.
Species Reactivity
  • Human
  • Mouse
Species Reactivity NoteHuman and mouse. Not tested in other species.
Antibody TypePolyclonal Antibody
Entrez Gene Number
Gene Symbol
  • EC 1.14.11
  • KDM6B
  • KIAA0346
Purification MethodProtein G Chromatography
UniProt Number
UniProt SummaryFUNCTION: Histone demethylase that specifically demethylates 'Lys-27' of histone H3, thereby playing a central role in histone code. Demethylates trimethylated and dimethylated H3 'Lys-27'. Plays a central role in regulation of posterior development, by regulating HOX gene expression. Involved in inflammatory response by participating in macrophage differentiation in case of inflammation by regulating gene expression and macrophage differentiation. Ref.5 Ref.6

Cofactor Ascorbate By similarity.

Fe(2+). Ref.5

SUBUNIT STRUCTURE: Interacts with TLE1 By similarity. Component of the MLL4 complex, at least composed of MLL4, ASH2L, RBBP5, WDR5, and JMJD3.

SUBCELLULAR lOCATION: NucleusProbable.

INDUCTION: By 12-O-tetradecanoylphorbol-13-acetate (TPA) in myeloid leukemia cells. Ref.4

SIMILARITY: Belongs to the UTX family.

Contains 1 JmjC domain.

Molecular Weight~180 kDa
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Quality AssuranceImmunocytochemisty:
Recognizes JMJD3 in HeLa, NIH 3T3, and A431 cells by cytochemistry (1:50 – 1:100 dilution).
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsStable for 1 year at 2-8°C from date of receipt.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial to pellet the solution. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Packaging Information
Material Size400 µL
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Número de referencia GTIN
07-1533 04053252328855

Documentation

Anti-JMJD3 (NT) Antibody Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

Anti-JMJD3 (NT) Antibody Certificados de análisis

CargoNúmero de lote
Anti-JMJD3 (N-terminus) - 2398823 2398823
Anti-JMJD3 (N-terminus) - 2459015 2459015
Anti-JMJD3 (N-terminus) - NG1809719 NG1809719
Anti-JMJD3 (N-terminus) - 2007353 2007353
Anti-JMJD3 (N-terminus) - 2036694 2036694
Anti-JMJD3 (N-terminus) - 2168272 2168272
Anti-JMJD3 (N-terminus) - 3062789 3062789
Anti-JMJD3 (N-terminus) - 3220371 3220371
Anti-JMJD3 (N-terminus) - 3837080 3837080
Anti-JMJD3 (N-terminus) - 4057967 4057967

Referencias bibliográficas

Visión general referenciasPub Med ID
Polycomb eviction as a new distant enhancer function.
Vernimmen, D; Lynch, MD; De Gobbi, M; Garrick, D; Sharpe, JA; Sloane-Stanley, JA; Smith, AJ; Higgs, DR
Genes & development  25  1583-8  2010

Mostrar resumen
21828268 21828268
Carcinoma in situ testis displays permissive chromatin modifications similar to immature foetal germ cells.
Almstrup, K; Nielsen, JE; Mlynarska, O; Jansen, MT; Jørgensen, A; Skakkebæk, NE; Rajpert-De Meyts, E
British journal of cancer  103  1269-76  2009

Mostrar resumen
20823885 20823885